JP2020036595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020036595A5 JP2020036595A5 JP2019195331A JP2019195331A JP2020036595A5 JP 2020036595 A5 JP2020036595 A5 JP 2020036595A5 JP 2019195331 A JP2019195331 A JP 2019195331A JP 2019195331 A JP2019195331 A JP 2019195331A JP 2020036595 A5 JP2020036595 A5 JP 2020036595A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- polypeptide
- cells
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 229920001184 polypeptide Polymers 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004748 cultured cell Anatomy 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 241000282465 Canis Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 241000235058 Komagataella pastoris Species 0.000 claims 1
- 230000001464 adherent effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443281P | 2017-01-06 | 2017-01-06 | |
| US62/443,281 | 2017-01-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517981A Division JP6609724B1 (ja) | 2017-01-06 | 2018-01-05 | 抗ヒト４−１ｂｂ抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020036595A JP2020036595A (ja) | 2020-03-12 |
| JP2020036595A5 true JP2020036595A5 (https=) | 2021-07-26 |
| JP7153626B2 JP7153626B2 (ja) | 2022-10-14 |
Family
ID=62791389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517981A Active JP6609724B1 (ja) | 2017-01-06 | 2018-01-05 | 抗ヒト４−１ｂｂ抗体およびその使用 |
| JP2019195331A Active JP7153626B2 (ja) | 2017-01-06 | 2019-10-28 | 抗ヒト４－１ｂｂ抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517981A Active JP6609724B1 (ja) | 2017-01-06 | 2018-01-05 | 抗ヒト４−１ｂｂ抗体およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10174122B2 (https=) |
| EP (2) | EP4032911A1 (https=) |
| JP (2) | JP6609724B1 (https=) |
| KR (2) | KR102427192B1 (https=) |
| CN (2) | CN112210010B (https=) |
| AU (3) | AU2018206015B2 (https=) |
| BR (1) | BR112019007714B1 (https=) |
| CA (1) | CA3039772C (https=) |
| ES (1) | ES2905890T3 (https=) |
| MX (1) | MX374810B (https=) |
| RU (1) | RU2725811C1 (https=) |
| SG (2) | SG10201914064QA (https=) |
| WO (1) | WO2018127787A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| CN112210010B (zh) | 2017-01-06 | 2023-12-05 | 优特力克斯有限公司 | 抗-人4-1bb抗体及其应用 |
| KR20240017409A (ko) | 2017-04-13 | 2024-02-07 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| AU2018301393B2 (en) | 2017-07-11 | 2025-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| WO2019036855A1 (en) * | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| CN112739339B (zh) | 2018-07-23 | 2024-12-27 | 海德堡医药研究有限责任公司 | 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| KR102259473B1 (ko) | 2018-08-10 | 2021-06-02 | 추가이 세이야쿠 가부시키가이샤 | 항cd137 항원 결합 분자 및 그의 사용 |
| SG11202102335YA (en) * | 2018-09-12 | 2021-04-29 | Eucure Beijing Biopharma Co Ltd | Anti-tnfrsf9 antibodies and uses thereof |
| WO2020077635A1 (zh) | 2018-10-19 | 2020-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗cd137抗体及其应用 |
| CN113286825B (zh) * | 2018-11-30 | 2024-06-18 | 爱必乐生物公司 | 抗pd-l1/抗4-1bb双特异性抗体及其用途 |
| CN120098128A (zh) | 2019-01-02 | 2025-06-06 | Qlsf生物治疗药物公司 | Cd137激动剂抗体及其用途 |
| NZ781538A (en) | 2019-04-24 | 2025-12-19 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| CN118526580A (zh) * | 2019-06-21 | 2024-08-23 | 瑞泽恩制药公司 | 结合psma和cd3的双特异性抗原结合分子与4-1bb共刺激组合的用途 |
| CA3160765A1 (en) | 2019-12-10 | 2021-06-17 | Abl Bio, Inc. | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof |
| WO2021132746A1 (en) * | 2019-12-24 | 2021-07-01 | Abl Bio, Inc. | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof |
| CN113045657B (zh) * | 2019-12-26 | 2022-06-07 | 杭州济元基因科技有限公司 | 一种人源化抗人bcma单克隆抗体及其car-t细胞 |
| TWI895351B (zh) * | 2020-02-12 | 2025-09-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| KR20220148209A (ko) * | 2020-02-28 | 2022-11-04 | 상하이 헨리우스 바이오테크, 인크. | 항cd137 작제물 및 그 용도 |
| JP2023518000A (ja) * | 2020-03-13 | 2023-04-27 | ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク | Ｒｏｒ２をターゲティングする、親和性成熟ヒト化結合性ドメイン |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| EP4163301B1 (en) * | 2020-06-11 | 2025-10-01 | Iwate Medical University | Humanized anti-gpc-1 antibody |
| KR20230042524A (ko) | 2020-08-07 | 2023-03-28 | 주식회사 유틸렉스 | 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도 |
| CN114075287B (zh) | 2020-08-18 | 2023-07-21 | 湖南远泰生物技术有限公司 | 人源化bcma抗体和bcma-car-t细胞 |
| CN116615442A (zh) * | 2020-09-08 | 2023-08-18 | 优特力克斯有限公司 | 程序性细胞死亡1多肽变体 |
| CN114195894B (zh) * | 2020-09-17 | 2025-02-25 | 普米斯生物技术(珠海)有限公司 | 一种靶向4-1bb的抗体及其应用 |
| WO2022148413A1 (zh) * | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | 特异性结合4-1bb的抗体及其抗原结合片段 |
| IL304295B2 (en) * | 2021-01-08 | 2025-07-01 | Beijing Hanmi Pharmaceutical Co Ltd | Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof |
| KR102618718B1 (ko) * | 2021-01-11 | 2023-12-29 | 주식회사 유틸렉스 | 항-4-1bb 항체 및 pd-1 단백질 또는 이의 단편을 포함하는 이중특이적 에피토프 결합 단백질 및 이의 용도 |
| WO2023030258A1 (en) * | 2021-08-31 | 2023-03-09 | LaNova Medicines Limited | Anti-4-1bb nanobodies |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025106539A1 (en) * | 2023-11-14 | 2025-05-22 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68928427T2 (de) | 1988-09-15 | 1998-06-04 | Univ Columbia | Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| WO1998034957A1 (en) | 1997-02-11 | 1998-08-13 | Immunomedics, Inc. | STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE α-GALACTOSYL EPITOPE |
| CA2309598A1 (en) | 1997-11-10 | 1999-05-20 | Mochida Pharmaceutical Co., Ltd. | Preventives and remedies for diffuse lung disease |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| EP1230268B1 (en) | 1999-11-18 | 2009-10-14 | Pharmexa Inc. | Heteroclitic analogs of class i epitopes |
| EP1235848A4 (en) | 1999-12-10 | 2005-02-09 | Epimmune Inc | INDUCING CELLULAR IMMUNE RESPONSES TO CARCINOEMBRYONIC ANTIGEN USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS |
| CN102764425B (zh) | 2000-08-21 | 2015-11-25 | 阿皮托普技术(布里斯托尔)有限公司 | 肽选择方法 |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| KR100468321B1 (ko) * | 2001-02-08 | 2005-01-27 | 학교법인 울산공업학원 | 종양 및 에이즈치료용 폴리펩타이드 |
| EP2149381A3 (en) | 2001-03-09 | 2010-05-05 | Baylor Research Institute | Method of treating malignancies through induction of blood immune responses |
| US7651686B2 (en) | 2001-10-09 | 2010-01-26 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by 4-1bb-binding agents |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| KR100500286B1 (ko) | 2002-07-02 | 2005-07-11 | 현대모비스 주식회사 | 자동차용 램프 스위치 장치 |
| AU2003243151A1 (en) | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| KR100500283B1 (ko) | 2003-03-25 | 2005-07-11 | 이뮤노믹스 주식회사 | 인간 4-1비비 분자에 대한 인간화 모노클로날 폴리펩티드 및 이를 포함하는 약학 조성물 |
| TW200502391A (en) | 2003-05-08 | 2005-01-16 | Xcyte Therapies Inc | Generation and isolation of antigen-specific t cells |
| US20050011582A1 (en) | 2003-06-06 | 2005-01-20 | Haug Jeffrey S. | Fluid delivery system for a flow cytometer |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| AR046094A1 (es) * | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| KR100694508B1 (ko) * | 2005-05-24 | 2007-03-13 | 울산대학교 산학협력단 | Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법 |
| PT2016414E (pt) | 2006-05-05 | 2015-11-24 | Opexa Therapeutics | Vacina de células t |
| KR100882445B1 (ko) | 2007-03-16 | 2009-02-09 | 울산대학교 산학협력단 | 항―４－１ｂｂ 항체를 이용한 항원 특이적 자가유래ｃｄ８＋ｔ 세포의 분리 및 증식 방법 |
| KR101103603B1 (ko) | 2008-07-25 | 2012-01-09 | 국립암센터 | 4-1ｂｂｌ 펜타머 단백질을 이용한 항원 특이적 ｃｄ８＋ｔ 세포의 분리 및 증식 방법 |
| RS53782B1 (sr) | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| KR20100043130A (ko) | 2008-10-18 | 2010-04-28 | 울산대학교 산학협력단 | 세포 활성 조성물 |
| US10817851B2 (en) | 2009-12-23 | 2020-10-27 | Aristocrat Technologies Australia Pty Limited | System and method for cashless gaming |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| AU2013207669C1 (en) | 2012-01-13 | 2018-05-31 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| US10899840B2 (en) * | 2014-02-04 | 2021-01-26 | Pfizer Inc. | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| MX2016014434A (es) * | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion. |
| CN106413751A (zh) | 2014-05-21 | 2017-02-15 | 辉瑞大药厂 | 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合 |
| EP3183269A2 (en) * | 2014-08-22 | 2017-06-28 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| KR20180016972A (ko) * | 2015-02-22 | 2018-02-20 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Cd137에 결합하는 항체 치료제 |
| MY193229A (en) * | 2015-06-16 | 2022-09-26 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
| WO2017205745A1 (en) * | 2016-05-27 | 2017-11-30 | Abbvie Biotherapeutics Inc. | Anti-4-1bb antibodies and their uses |
| GB201619648D0 (en) * | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| CN112210010B (zh) | 2017-01-06 | 2023-12-05 | 优特力克斯有限公司 | 抗-人4-1bb抗体及其应用 |
| CN119193493A (zh) | 2017-12-08 | 2024-12-27 | 朱诺治疗学股份有限公司 | 生产工程化t细胞组合物的过程 |
| JP2021533759A (ja) | 2018-08-10 | 2021-12-09 | ユーティレックス カンパニー リミテッド | 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法 |
-
2018
- 2018-01-05 CN CN202011039658.5A patent/CN112210010B/zh active Active
- 2018-01-05 AU AU2018206015A patent/AU2018206015B2/en active Active
- 2018-01-05 EP EP21211128.0A patent/EP4032911A1/en active Pending
- 2018-01-05 CN CN201880005123.0A patent/CN110392696B/zh active Active
- 2018-01-05 JP JP2019517981A patent/JP6609724B1/ja active Active
- 2018-01-05 MX MX2019004692A patent/MX374810B/es active IP Right Grant
- 2018-01-05 US US15/863,526 patent/US10174122B2/en active Active
- 2018-01-05 SG SG10201914064QA patent/SG10201914064QA/en unknown
- 2018-01-05 BR BR112019007714-6A patent/BR112019007714B1/pt active IP Right Grant
- 2018-01-05 CA CA3039772A patent/CA3039772C/en active Active
- 2018-01-05 ES ES18736336T patent/ES2905890T3/es active Active
- 2018-01-05 EP EP18736336.1A patent/EP3523332B1/en active Active
- 2018-01-05 KR KR1020207006944A patent/KR102427192B1/ko active Active
- 2018-01-05 SG SG11201903021WA patent/SG11201903021WA/en unknown
- 2018-01-05 KR KR1020197015730A patent/KR102089072B1/ko active Active
- 2018-01-05 RU RU2019116731A patent/RU2725811C1/ru active
- 2018-01-05 WO PCT/IB2018/000043 patent/WO2018127787A1/en not_active Ceased
- 2018-11-14 US US16/191,381 patent/US10919972B2/en active Active
-
2019
- 2019-07-05 AU AU2019204847A patent/AU2019204847B2/en active Active
- 2019-10-28 JP JP2019195331A patent/JP7153626B2/ja active Active
-
2020
- 2020-02-13 US US16/790,299 patent/US10774151B2/en active Active
-
2021
- 2021-01-26 US US17/158,474 patent/US11859004B2/en active Active
- 2021-04-22 AU AU2021202474A patent/AU2021202474A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020036595A5 (https=) | ||
| US11987635B2 (en) | Anti-4-1BB antibodies and methods of making and using thereof | |
| US9758583B2 (en) | Anti-CTLA-4 antibodies | |
| CA2973332C (en) | Anti-pd-l1 antibodies | |
| RU2715628C2 (ru) | Антитела к pd-1 | |
| CA3015938A1 (en) | Anti-lag-3 antibodies | |
| WO2018036473A1 (zh) | 抗ctla4-抗pd-1双功能抗体、其药物组合物及其用途 | |
| CN106977602A (zh) | 一种抗 pd1 单克隆抗体、其药物组合物及其用途 | |
| CN106699891A (zh) | 一种抗pd‑l1 抗体、其药物组合物及其用途 | |
| JP2022044795A (ja) | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション | |
| CN108218990A (zh) | 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用 | |
| JP2018521959A5 (https=) | ||
| CN115461373A (zh) | 密蛋白18.2的抗体及其用途 | |
| JP2020528765A5 (https=) | ||
| JPWO2006046661A1 (ja) | インターロイキン−６阻害剤 | |
| Peterson | Advances in monoclonal antibody technology: genetic engineering of mice, cells, and immunoglobulins | |
| CN110938146B (zh) | Tim-3单域抗体及其应用 | |
| US20260008861A9 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| CN118108845B (zh) | 一种靶向B7-H3的CAR-γδT细胞的制备方法及应用 | |
| WO2020020275A1 (zh) | 人源化抗人ctla4单克隆抗体及其制备方法和用途 | |
| CN108546299B (zh) | 解除pd-1对机体免疫抑制的靶向分子 | |
| WO2024238287A1 (en) | Dual blocking and chimeric cytokine receptor | |
| CN116178527A (zh) | 抗sar-cov-2全人源单克隆抗体6g18及其制法与应用 | |
| CN116023475A (zh) | 抗sar-cov-2全人源单克隆抗体及其制法与应用 | |
| CN121159672A (zh) | 靶向人乳头瘤病毒的抗体及应用 |